Zobrazeno 1 - 10
of 56
pro vyhledávání: '"L I, Pavlova"'
Autor:
M. S. Vorob’Eva, M. N. Rashchepkina, L. I. Pavlova, L. D. Bystritsky, N. H. Stavitskaya, T. E. Iltchenko, G. P. Bilalova, I. A. Mishchenko, O. I. Sharova
Publikováno v:
Бюллетень сибирской медицины, Vol 5, Iss 0, Pp 63-71 (2006)
The high rate of tick-borne encephalitis (TBE) morbidity is lasting for recent years in many areas of Russian Federation. Vac- cination with TBE vaccine is considered to be most effective mean of TBE prophylaxis in endemic areas. VIRION branch (in To
Externí odkaz:
https://doaj.org/article/ccaf0a57bc0343eca9a5ec7904b9676f
Autor:
L. I. Olbinskaya, T. E. Morozova, B. G. Kukes, V. S. Zadionchenko, L. I. Pavlova, D. M. Sychev, I. V. Pogochenkova, Z. O. Grineva
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 5, Pp 70-73 (2002)
Antianginal and anti2ischemic effectiveness and tolerability of oxicardin in patients with stable angina of I-III functional classes: results of a Russian multicenter Russia.
Externí odkaz:
https://doaj.org/article/55b860de17ba4ce48ae7468d2ba7d817
Autor:
G. P. Bilalova, I. A. Mishchenko, L. D. Bystritsky, N. H. Stavitskaya, L. I. Pavlova, O. I. Sharova, M. S. Vorob’Eva, T. E. Iltchenko, M. N. Rashchepkina
Publikováno v:
Bûlleten' Sibirskoj Mediciny, Vol 5, Iss 0, Pp 63-71 (2006)
The high rate of tick-borne encephalitis (TBE) morbidity is lasting for recent years in many areas of Russian Federation. Vac- cination with TBE vaccine is considered to be most effective mean of TBE prophylaxis in endemic areas. VIRION branch (in To
Publikováno v:
Klinicheskaia meditsina. 80(10)
The results of a comparative clinicopharmacological study of adalate, foridone, siskor and lomir effects on cerebral and peripheral blood flow are presented for 46 patients with arterial hypertension stage I-III. It was found that all the four drugs
Publikováno v:
Klinicheskaia meditsina. 80(8)
Antianginal and hypotensive efficacy of etizem was studied in 40 patients with ischemic heart disease (IHD), stable angina of effort (moderate-to-severe) for 4 weeks and 43 patients with arterial hypertension (mild-to-moderate) for 12 weeks. A course
Autor:
A V, Noskova, M A, Gorbunov, L I, Pavlova, G A, El'shina, I S, Sharipova, L G, Karpovich, T I, Kalashnikova, T A, Bektimirov, V V, Rikhmer, V S, El'nikov
Publikováno v:
Voprosy virusologii. 45(6)
This paper sums up the results of controlled field clinical trials of adult and childhood variants of Harvix, inactivated vaccine from hepatitis A. The vaccine is weakly reactogenic and safe. After a single injection of Harvix-1440 vaccine to adults
Autor:
N V, Perova, I N, Ozerova, I V, Paramonova, A M, Olfer'ev, N M, Akhmedzhanov, L I, Pavlova, R G, Oganov
Publikováno v:
Bulletin of experimental biology and medicine. 131(4)
We studied phospholipid composition of high-density lipoproteins in patients with normo- and hypertriglyceridemia treated with various hypolipidemic preparations (simvastatin and fenofibrate). Both preparations changed phospholipid composition of hig
Autor:
L I, Pavlova, M A, Gorbunov, M S, Vorob'eva, A S, Karavanov, V P, Grachev, I P, Ladyshenskaia, M N, Rasshchepkina, L N, Mel'nikova, T M, Lebedeva, N A, Mel'nikov, A G, Gusmanova, M Iu, Deviatkov, E V, Rozanova, M A, Mukachev
Publikováno v:
Zhurnal mikrobiologii, epidemiologii i immunobiologii. (6)
The word deals with the results obtained in the study of the reactogenicity and immunological activity of concentrated and inactivated tissue-culture tick-borne encephalitis vaccine, manufactured by the Chumakov Institute of Poliomyelitis and Viral E
Autor:
M A, Gorbunov, A V, Noskova, G A, El'shina, T A, Bektimirov, L I, Pavlova, L A, Aksenov, A A, Ivanov
Publikováno v:
Voprosy virusologii. 45(1)
Controlled field clinical trials of Avaxim vaccine from hepatitis A (Pasteur-Merrier-Connot) were carried out in adults and children aged 3-14 years to evaluate its reactogenicity and antigenic properties. The vaccine was weakly reactogenic both in a
Publikováno v:
Zhurnal mikrobiologii, epidemiologii i immunobiologii. (2)
The results of the field trials of the vaccine "Act-Hib" against Haemophilus influenzae of type b, presented for registration by Pasteur Mérieux Connaught (France), are summarized. The vaccine was found to have low reactogenicity and high immunologi